Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Average (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Equity Average for 12 consecutive years, with $614.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 19.79% to $614.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $614.2 million, a 19.79% decrease, with the full-year FY2025 number at $678.5 million, up 17.02% from a year prior.
  • Equity Average was $614.2 million for Q4 2025 at Madrigal Pharmaceuticals, down from $660.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $853.9 million in Q2 2024 to a low of $47.1 million in Q3 2022.
  • A 5-year average of $388.7 million and a median of $251.5 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 81.37% in 2022, then skyrocketed 1199.57% in 2024.
  • Madrigal Pharmaceuticals' Equity Average stood at $215.5 million in 2021, then tumbled by 51.73% to $104.0 million in 2022, then surged by 105.51% to $213.8 million in 2023, then skyrocketed by 258.19% to $765.8 million in 2024, then dropped by 19.79% to $614.2 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Equity Average are $614.2 million (Q4 2025), $660.9 million (Q3 2025), and $703.3 million (Q2 2025).